Science Explorer Back to mapMap
Discussion
Company · Pointe-Claire · Canada

Telesta Therapeutics (Canada)

telestatherapeutics.comROR OpenAlex
Research works
6
▲ 586% vs 2018-21
Citations
139
21.6 per fractional work
Top-10% rate
18.8%
all institutions 10.0%
Open access
69%
world 40%
International
66%
world 18%
Telesta Therapeutics (Canada)

Not ranked overall: Telesta Therapeutics (Canada) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Telesta Therapeutics (Canada) work in?

In all years, 56% of research at Telesta Therapeutics (Canada) is in Life Sciences, 43% in Health Sciences. Its largest fields are Medicine (43%), Biochemistry, Genetics and Molecular Biology (42%), Immunology and Microbiology (10%). It does 1.7× the world's share of Life Sciences.

Life Sciences: 4 fractional works · 55.6% of its workBiochemistry, Genetics and Molecular Biology: 3 fractional works · 41.6% of its workMolecular Biology: 2 fractional works · 29.3% of its workGenetics: 0 fractional works · 4.3% of its workCancer Research: 0 fractional works · 4.2% of its workCell Biology: 0 fractional works · 2.0% of its workBiochemistry: 0 fractional works · 1.7% of its workImmunology and Microbiology: 1 fractional works · 10.1% of its workImmunology: 1 fractional works · 10.1% of its workNeuroscience: 0 fractional works · 3.9% of its workCellular and Molecular Neuroscience: 0 fractional works · 3.9% of its workHealth Sciences: 3 fractional works · 42.7% of its workMedicine: 3 fractional works · 42.7% of its workOncology: 1 fractional works · 14.3% of its workSurgery: 0 fractional works · 6.8% of its workEpidemiology: 0 fractional works · 6.5% of its workPulmonary and Respiratory Medicine: 0 fractional works · 4.0% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 3.9% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 2.6% of its workGenetics: 0 fractional works · 1.2% of its workObstetrics and Gynecology: 0 fractional works · 1.2% of its workPhysiology: 0 fractional works · 1.2% of its workNeurology: 0 fractional works · 0.8% of its workPhysical Sciences: 0 fractional works · 1.7% of its workChemistry: 0 fractional works · 1.7% of its workOrganic Chemistry: 0 fractional works · 1.7% of its workALL ITS WORKTelestaTherapeutics…6fractional works, all years
Life Sciences56%Physical Sciences2%Health Sciences43%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 5 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology341.6%
    2. Immunology and Microbiology110.1%
    3. Neuroscience03.9%
    1. Medicine342.7%
    1. Chemistry01.7%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Telesta Therapeutics (Canada)?

The most cited paper from Telesta Therapeutics (Canada) is "CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition" (David Gallo et al., 2022), with 245 citations. Next come "The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer" (128) and "Targeting ATR in patients with cancer" (98).

Most cited papers
#PaperReleasedCitations
1 CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition David Gallo et al. · Nature Open access 20 Apr 2022 245
2 The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer Salomé Adam et al. · Nature Cancer Open access 11 Nov 2021 128
3 Targeting ATR in patients with cancer Natalie Y.L. Ngoi, Patrick Glen Pilie, Daniel James McGrail et al. · Nature Reviews Clinical Oncology Review 20 Feb 2024 98
4 Synthetic lethal strategies for the development of cancer therapeutics Natalie Y.L. Ngoi, David Gallo, Carlos Torrado et al. · Nature Reviews Clinical Oncology Review 3 Dec 2024 72
5 Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients Roger Li, John Amrhein, Zvi R. Cohen et al. · Bladder Cancer Open access 9 Nov 2016 37
All 19 most cited papers, with filters and sorting

Which research topics does Telesta Therapeutics (Canada) publish most on?

By volume in 2022-now: PARP inhibition in cancer therapy, DNA Repair Mechanisms, interferon and immune responses and Influenza Virus Research Studies.

PARP inhibition in cancer therapy: 1 fractional worksDNA Repair Mechanisms: 0 fractional worksinterferon and immune re…0interferon and immune responses: 0 fractional worksInfluenza Virus Research…0Influenza Virus Research Studies: 0 fractional worksUbiquitin and proteasome pathways: 0 fractional worksNuclear Receptors and Signaling: 0 fractional worksHormonal Regulation and …0Hormonal Regulation and Hypertension: 0 fractional worksCell death mechanisms and regulation: 0 fractional worksEffects of Radiation Exposure: 0 fractional worksCancer Genomics and Diagnostics: 0 fractional works
OncologyMolecular BiologyImmunologyEpidemiology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 PARP inhibition in cancer therapy Oncology 1 works
  2. 2 DNA Repair Mechanisms Molecular Biology 0 works
  3. 3 interferon and immune responses Immunology 0 works
  4. 4 Influenza Virus Research Studies Epidemiology 0 works
  5. 5 Ubiquitin and proteasome pathways Molecular Biology 0 works
  6. 6 Nuclear Receptors and Signaling Cellular and Molecular Neuroscience 0 works
  7. 7 Hormonal Regulation and Hypertension Endocrinology, Diabetes and Metabolism 0 works
  8. 8 Cell death mechanisms and regulation Molecular Biology 0 works
  9. 9 Effects of Radiation Exposure Radiology, Nuclear Medicine and Imaging 0 works
  10. 10 Cancer Genomics and Diagnostics Cancer Research 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available69.2%not open30.8%

World: 40% of research is openly available.

with international co-authors66.2%domestic only33.8%

World: 18% is written across borders.

How has Telesta Therapeutics (Canada)'s research output changed?

Output in 2022-2025 was 586% higher than in 2018-2021.

still counting20202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Pointe-Claire

All research institutions in Pointe-Claire

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Telesta Therapeutics (Canada). Posts are plain text and can be reported.